Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.

× No keyword cloud information.

10 in total

1. Association of serum uric acid with blood pressure in Japanese men. Cross-sectional study in work-site group.

Authors: Yasuo Kansui; Toshio Ohtsubo; Kenichi Goto; Satoko Sakata; Kunihiko Ichishima; Masayo Fukuhara; Yuko Ohta; Kiyoshi Matsumura
Journal: Circ J Date: 2011-10-15 Impact factor: 2.993

2. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors: Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245

3. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.

Authors: Hiroki Omori; Noritaka Kawada; Kazunori Inoue; Yoshiyasu Ueda; Ryohei Yamamoto; Isao Matsui; Jyunya Kaimori; Yoshitsugu Takabatake; Toshiki Moriyama; Yoshitaka Isaka; Hiromi Rakugi
Journal: Clin Exp Nephrol Date: 2012-02-18 Impact factor: 2.801

4. Hyperuricemia is a significant risk factor for the onset of chronic kidney disease.

Authors: Akiko Toda; Yuko Ishizaka; Mizuki Tani; Minoru Yamakado
Journal: Nephron Clin Pract Date: 2014-01-15

5. Acute renal and hepatic failure associated with allopurinol treatment.

Authors: R M Fagugli; G Gentile; G Ferrara; R Brugnano
Journal: Clin Nephrol Date: 2008-12 Impact factor: 0.975

Review 6. Uric acid: A marker of increased cardiovascular risk.

Authors: Ana C M Gagliardi; Marcio H Miname; Raul D Santos
Journal: Atherosclerosis Date: 2008-05-21 Impact factor: 5.162

7. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.

Authors: Sima Halevy; Pierre-Dominique Ghislain; Maja Mockenhaupt; Jean-Paul Fagot; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Luigi Naldi; Ariane Dunant; Cecile Viboud; Jean-Claude Roujeau
Journal: J Am Acad Dermatol Date: 2007-10-24 Impact factor: 11.527

8. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.

Authors: Laura G Sánchez-Lozada; Edilia Tapia; Virgilia Soto; Carmen Avila-Casado; Martha Franco; Jerry L Wessale; Lin Zhao; Richard J Johnson
Journal: Nephron Physiol Date: 2008-04-24

9. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.

Authors: S Kobayashi; M Ogura; T Hosoya
Journal: J Clin Pharm Ther Date: 2013-03-18 Impact factor: 2.512

10. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.

Authors: Laura G Sánchez-Lozada; Edilia Tapia; Virgilia Soto; Carmen Avila-Casado; Martha Franco; Lin Zhao; Richard J Johnson
Journal: Nephrol Dial Transplant Date: 2007-11-29 Impact factor: 5.992

10 in total

1 in total

1. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).

Authors: Sawako Kato; Masahiko Ando; Toshihiro Mizukoshi; Takanobu Nagata; Takayuki Katsuno; Tomoki Kosugi; Naotake Tsuboi; Shoichi Maruyama
Journal: Nagoya J Med Sci Date: 2016-05 Impact factor: 1.131

1 in total